In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of India’s premiere pharmaceutical companies.

In 1978, Fourteen years later, the company had outgrown the startup phase and was incorporated as a private limited company. Jagsonpal was now a fast growing pharmaceutical company. The firm was committed to healing India with quality pharmaceutical products and had its eyes firmly set on becoming one of the country’s leading pharmaceutical companies.

In 1986 Jagsonpal went public on the BSE. This was the first time the firm had tapped the capital markets.

In 1994 the company was listed on the NSE. This trait of not being content with the status quo has become a core part of Jagsonpal’s company culture. Commitment to growth is ingrained in the very soul of the company and this is reflected in the Jagsonpal’s current aggressive growth strategy.

Jagsonpal is among India’s premiere pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.

The firm’s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation.

Product range of the company includes:

 * Dextropropoxyphene
 * Tolnaftate 
 * Indocap SR
 *  Sterile Unipacks 
 * Thiopental sodium

Jagsonpal Pharmaceuticals Ltd.

Bajaj Healthcare Ltd.

SMS Pharmaceuticals Ltd.

Solara Active Pharma Sciences Ltd.

NGLFINE

Zota Health Care Ltd.

Panacea Biotec Ltd.

Kopran Ltd.

Hester Biosciences Ltd.

Windlas Biotech Ltd.

Lincoln Pharmaceuticals Ltd.

Sakar Healthcare Ltd.

Medicamen Biotech Ltd.

Bliss GVS Pharma Ltd.

Nectar Lifesciences Ltd.

Market Cap	1,093 Cr	ROE	18.9%
P/E Ratio(TTM)	38.6	EPS(TTM)	0.0
P/B Ratio	6.5	Dividend Yield	1.2%
Industry P/E	40.0	Book Value	64.7
		Face Value	5.0

Fundamentals